A Case of Etanercept Induced Palmoplantar Pustular Psoriasis

Observations: Etanercept is a human recombinant soluble tumor necrosis factor  (TNF-α) receptor fusion protein. Etanercept has been used successfully to treat a wide range of inflammatory disorders including psoriasis and psoriatic arthritis resistant to classical disease-modifying treatments. The...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the Turkish Academy of Dermatology 2012-09, Vol.6 (3)
Main Author: Takçı, Zennure
Format: Article
Language:English
Subjects:
Psoriasis
Tumor necrosis factor-TNF
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Observations: Etanercept is a human recombinant soluble tumor necrosis factor  (TNF-α) receptor fusion protein. Etanercept has been used successfully to treat a wide range of inflammatory disorders including psoriasis and psoriatic arthritis resistant to classical disease-modifying treatments. The widespread use of TNF-α antagonists led to the recognition of adverse effects. Herein, we report a case of palmoplantar pustular psoriasis in a 37-year-old man during the etanercept therapy.
ISSN:1307-394X
1307-394X
DOI:10.6003/jtad1263c3